KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Work In Process (2016 - 2025)

Astrazeneca has reported Work In Process over the past 11 years, most recently at $2.8 billion for Q4 2025.

  • Quarterly results put Work In Process at $2.8 billion for Q4 2025, up 21.69% from a year ago — trailing twelve months through Dec 2025 was $2.8 billion (up 21.69% YoY), and the annual figure for FY2025 was $2.8 billion, up 21.69%.
  • Work In Process for Q4 2025 was $2.8 billion at Astrazeneca, up from $2.3 billion in the prior quarter.
  • Over the last five years, Work In Process for AZN hit a ceiling of $5.2 billion in Q4 2021 and a floor of $1.9 billion in Q4 2022.
  • Median Work In Process over the past 5 years was $2.3 billion (2023), compared with a mean of $2.9 billion.
  • Biggest five-year swings in Work In Process: soared 291.89% in 2021 and later tumbled 64.26% in 2022.
  • Astrazeneca's Work In Process stood at $5.2 billion in 2021, then tumbled by 64.26% to $1.9 billion in 2022, then rose by 24.73% to $2.3 billion in 2023, then fell by 1.85% to $2.3 billion in 2024, then rose by 21.69% to $2.8 billion in 2025.
  • The last three reported values for Work In Process were $2.8 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.3 billion (Q4 2023) per Business Quant data.